中国真菌学杂志 2021, Vol. 16 Issue (2): 131-136.
黄薇, 张维, 李奇穗, 余庆, 邓长刚, 陈耀凯, 袁婧
收稿日期:2020-01-14
发布日期:2021-04-25
通讯作者:
袁婧,E-mail:yuanjingcq@outlook.com
E-mail:yuanjingcq@outlook.com
作者简介:黄薇,女(汉族),本科,住院医师.E-mail:1253950528@qq.com
基金资助:
Received:2020-01-14
Published:2021-04-25
中图分类号:
黄薇, 张维, 李奇穗, 余庆, 邓长刚, 陈耀凯, 袁婧. 艾滋病合并隐球菌脑膜炎的诊断及治疗[J]. 中国真菌学杂志, 2021, 16(2): 131-136.
| [1] Park BJ, Wannemuehler KA, Marston BJ, et al. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS[J]. AIDS, 2009, 23(4):525-530. [2] Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection[J]. Curr HIV Res, 2007, 5(3):355-360. [3] Manosuthi W, Chottanapund S, Sungkanuparph S. Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis[J]. J Acquir Immune Defic Syndr, 2008, 48(4):508-509. [4] UNAIDS. UNAIDS DATA 2020.[EB/OL]. (2020-7-6).https://www.unaids.org/en/resources/documents/2020/unaids-data. [5] Rajasingham R, Smith RM, Park BJ, et al. Global burden of disease of HIV-associated cryptococcal meningitis:an updated analysis[J]. Lancet Infect Dis, 2017, 17(8):873-881. [6] Pyrgos V. Epidemiology of cryptococcal meningitis in the US:1997-2009[J]. PloS One, 2013, 8(2):e56269. [7] Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures[J]. AIDS, 2009, 23(6):701-706. [8] Senadim S, Alpaydin Baslo S, Tekin Güveli B, et al. A rare cause of cerebral venous thrombosis:cryptococcal meningoencephalitis[J]. Neurol Sci, 2016, 37(7):1145-1148. [9] Lan SH, Chang WN, Lu CH, et al. Cerebral infarction in chronic meningitis:a comparison of tuberculous meningitis and cryptococcal meningitis[J]. QJM, 2001, 94(5):247-253. [10] Vidal JE, Boulware DR. Lateral flow assay for cryptococcal antigen:an important advance to improve the continuum of HIV care and reduce cryptococcal meningitis-related mortality[J]. Rev Inst Med Trop Sao Paulo, 2015, 57(19):38-45. [11] Longley N, Jarvis JN, Meintjes G, et al. Cryptococcal antigen screening in patients initiating ART in South Africa:a prospective cohort study[J]. Clin Infect Dis, 2016, 62(5):581-587. [12] Jarvis, Joseph N, Lawn, et al.Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa[J]. Clin Infect Dis, 2009, 48(7):856-862. [13] Jarvis JN,Harrison TS,Lawn D, et al. Cost effectiveness of cryptococcal antigen screening as a strategy to prevent HIV-associated cryptococcal meningitis in South Africa[J]. PloS One, 2013, 8(7):1-10. [14] Jarvis JN,Bicanic T,Loyse A, et al. Determinants of mortality in a combined cohort of 501 patients with HIV-associated cryptococcal meningitis:implications for improving outcomes[J]. Clin Infect Dis, 2014, 58(5):736-745. [15] Bicanic T, Muzoora C, Brouwer AE, et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis:analysis of a combined cohort of 262 patients[J]. Clin Infect Dis, 2009, 49:702-709. [16] Adeyemi B, Ross A. Profile and mortality outcome of patients admitted with cryptococcal meningitis to an urban district hospital in KwaZulu-Natal,South Africa[J]. J Int AIDS Soc, 2014, 17(3):19623. [17] Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients:a randomized trial[J]. Clin Infect Dis, 2008, 47(1):123-130. [18] Jarvis JN, Meintjes G, Harrison TS, et al. Outcomes of cryptococcal meningitis inantiretroviral naive and experienced patients in South Africa[J]. J Infect, 2010, 60(6):496-498. [19] Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy[J]. Clin Infect Dis, 2008, 46(11):1694-1701. [20] Grant PM, Komarow L, Andersen J, et al. Riskfactor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection[J]. PLoS ONE,2010,5(7):e11416. [21] Vander H, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome[J]. N Engl J Med, 1997, 337(1):15-21. [22] Hamill RJ, Sobel JD, El-Sadr W, et al. Comparison of 2 doses of liposomal amphotericin B and conventional amphotericin B deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis:a randomized, double-blind clinical trial of efficacy and safety[J]. Clin Infect Dis, 2010, 51(2):225-532. [23] 鲁雁秋, 黄晓婕, 吴玉珊, 等. 203例艾滋病合并新型隐球菌性脑膜炎患者预后影响因素研究[J]. 中华神经医学杂志, 2018, 17(4):397-401. [24] 李太生, 王福生, 高福. 中国艾滋病诊疗指南(2018版)[J]. 中华内科杂志, 2018, 57(12):7-8. [25] Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome[J]. N Engl J Med, 1991, 324(9):580-584. [26] Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis[J]. N Engl J Med, 1992, 326(2):83-89. [27] Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis[J]. Clin Infect Dis, 1999, 28(2):291-296. [28] Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis[J]. Clin Infect Dis,2014,59(11):1607-1614. [29] Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures[J]. AIDS, 2009, 23(6):701-706. [30] Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis[J]. Clin Infect Dis, 2000, 30(1):47-54. [31] Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the infectious diseases society of America[J]. Clin Infect Dis, 2010, 50(3):291-322. [32] Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive dexamethasone in HIV-associated cryptococcal meningitis[J]. N Engl J Med, 2016, 374(6):542-554. [33] Meintjes G, Scriven J, Marais S. Management of immune reconstitution inflammatory syndrome[J]. Curr HIV/AIDS Rep, 2012, 9(3):138-150. [34] Bonham S, Meya DB, Bohjanen PR. Boulware DR (2008) Biomarkers of HIV immune reconstitution inflammatory syndrome[J]. Biomark Med, 2008, 2(4):349-361. [35] Manabe YC, Campbell JD, Sydnor E. Immune reconstitution inflammatory syndrome:risk factors and treatment implications[J]. J Acquir Immune Defic Syndr, 2007, 46(4):456-462. [36] Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis:a prospective study[J]. J Acquir Immune Defic Syndr, 2009, 51(4):130-134. [37] Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after Cryptococcus meningitis:a prospective cohort study[J]. PLoS Med, 2010, 7(12):e1000384. [38] Colombo ERDC, Mora DJ, Silva-Vergara ML. Immune reconstitution inflammatorysyndrome (IRIS) associated with Cryptococcus neoformans infection in AIDS patients[J]. Mycoses, 2011, 54(4):178-182. [39] Sungkanuparph S, Giller SG, Chetchotisakd P, et al. Cryptococcal immune reconstitution syndrome after antiretroviral therapy in AIDS patients with cryptococcal meningitis:a prospective multicenter study[J]. Clin Infect Dis, 2009, 49(6):931-934. [40] Boulware DR, Bonham SC, Meya DB, et al. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome[J]. J Infect Dis, 2010, 202(6):962-970. [41] Chang CC, Dorasamy AA, Gosnell BI, et al. Clinical and mycological predictors of cryptococcosis-associated immune reconstitution inflammatory syndrome[J]. AIDS, 2013, 27(13):2089-2099. [42] Haddow LJ, Easterbrook PJ, Mosam A, et al. Defining immune reconstitution inflammatory syndrome:evaluation of expert opinion versus 2 case definitions in a South African cohort[J]. Clin Infect Dis, 2009, 49(1):1424-1432. [43] Jarvis J.CSF cytokine profiles in patients with HIV-associated cryptococcal meningitis:correlates with clinical outcome[C]//the 8th International Conference on Cryptococcus and Cryptococcosis, Charleston, May 4, 2011. [44] Narayanan S, Banerjee C, Holt PA.Cryptococcal immune reconstitution syndrome during steroid withdrawal with hydroxychloroquine[J]. Internat J Infect Dis,2011, 15(1):70-73. [45] Scourfield A, Waters L, Tittle V, et al. Azathioprine use as a novel treatment for cryptococcal immune reconstitution and inflammatory syndrome in HIV[C]//17th Annual Conference of the British HIV Association, Bournemouth, 2011. [46] Brunel AS, Reynes J, Tuaillon E, et al. Thalidomide for steroid-dependent immune reconstitution inflammatory syndromes during AIDS[J]. AIDS, 2012, 26(16):2110-2111. [47] Sitapati AM, Kao CL, Cachay ER, et al.Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab[J]. Clin Infect Dis, 2010, 50(2):7-10. [48] Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution syndrome in HIV-1 infected individuals:proposed clinical case definitions[J]. Lancet Infect Dis, 2010, 10(11):791-802. [49] Baldassarre R, Mdodo R, Omonge E, et al. Mortality after clinical management of AIDS-associated cryptococcal meningitis[J]. East Afr Med J, 2014, 91(5):145-151. [50] David R, Boulware, David B, et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis[J]. N Engl J Med, 2014, 370(26):2487-2498. [51] Ingrid EW, Okwen MP, Marty R, et al. Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis[J].Cochrane Database Syst Rev, 2018, 7(7):CD009012. |
| [1] | 张馨予, 潘开素, 罗宏, 郑冬燕, 郑艳青, 曹存巍, 梁纲. 中药小檗碱协同抗真菌药对马尔尼菲篮状菌的体外药敏试验研究[J]. 中国真菌学杂志, 2021, 16(3): 176-181. |
| [2] | 刘晓, 宋营改, 李若瑜. 重症呼吸道病毒感染并发/继发侵袭性真菌感染[J]. 中国真菌学杂志, 2021, 16(3): 211-216. |
| [3] | 胡馨, 王延龙, 吕莎, 林怡彤, 李福秋. 5%阿莫罗芬搽剂治疗68例远端侧位甲下型甲真菌病的临床疗效观察[J]. 中国真菌学杂志, 2021, 16(2): 90-95,112. |
| [4] | 张春梅, 赵婷, 何晓莉, 彭雷. 真菌性食管炎患者抗真菌治疗期间血常规、免疫功能动态变化的特征分析[J]. 中国真菌学杂志, 2021, 16(2): 106-110. |
| [5] | 梁官钊, 刘维达. 2019年欧洲毛霉病诊疗指南解读[J]. 中国真菌学杂志, 2021, 16(2): 116-120. |
| [6] | 陈艳慧, 钟桥石, 杭亚平, 方雪瑶, 肖艳萍, 曹星卫, 朱鸿英, 罗红, 胡龙华. 耶氏肺孢子菌肺炎临床特点及KL-6诊断价值[J]. 中国真菌学杂志, 2021, 16(1): 19-23. |
| [7] | 李艺, 郭佳, 王竟爽, 印苏培, 赵景宏, 黄云剑. 维持性腹膜透析患者并发真菌性腹膜炎的易感因素和结局分析[J]. 中国真菌学杂志, 2021, 16(1): 29-34. |
| [8] | 董嘉琤, 梁官钊, 徐秀莲, 刘维达. 难治性孢子丝菌病1例[J]. 中国真菌学杂志, 2021, 16(1): 48-50. |
| [9] | 景丹蕤, 李筱芳, 刘维达. 卫凤莲暗色真菌感染病原学诊断方法和治疗药物研究进展[J]. 中国真菌学杂志, 2021, 16(1): 69-72. |
| [10] | 中国手癣和足癣诊疗指南工作组. 中国手癣和足癣诊疗指南(基层实践版2020)[J]. 中国真菌学杂志, 2020, 15(6): 325-330. |
| [11] | 季梅, 隗祎. 儿童脓癣2例[J]. 中国真菌学杂志, 2020, 15(6): 366-367,377. |
| [12] | 邢小微, 张家堂. 隐球菌性脑膜炎的诊断进展[J]. 中国真菌学杂志, 2020, 15(6): 378-380. |
| [13] | 特比萘芬临床应用专家共识工作组. 特比萘芬临床应用专家共识[J]. 中国真菌学杂志, 2020, 15(5): 257-261. |
| [14] | 王玲, 景东云, 王学军, 刘俊, 曹月清. 长脉宽Nd:YAG 1064 nm激光治疗远端侧位甲下型甲真菌病的疗效观察及对真菌超微结构的影响[J]. 中国真菌学杂志, 2020, 15(5): 268-273. |
| [15] | 陈易鑫, 闫师玲, 朱银民, 范静平, 陈晓平, 周恩晖, 薛晓成, 张燚. 真菌性鼻-鼻窦炎的CT影像诊断分析[J]. 中国真菌学杂志, 2020, 15(5): 283-287. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
